Io Biotech Posts Wider Loss in Q2
Io Biotech (NASDAQ:IOBT), a clinical-stage oncology company specializing in cancer vaccines, released its second quarter results on August 14, 2025. The most important update was the outcome of the pivotal Phase 3 trial for Cylembio®, its lead cancer vaccine candidate. The study demonstrated a clinical benefit by improving progression free survival in advanced melanoma, but it narrowly missed the statistical significance needed for regulatory approval. The company reported a net loss of $26.2 million for Q2 2025 (GAAP), deeper than the prior year’s loss, and a GAAP earnings per share figure of ($0.40). Revenue (GAAP) was zero, as widely expected for a clinical-stage biotech. Overall, the period underscored the risks and potential facing the company, with regulatory timing and funding runway now in sharper focus.
Source: Analyst estimates for the quarter provided by FactSet.
Io Biotech is developing immunotherapy treatments to help the body's immune system fight cancer. Its core technology, the T-win® platform, is designed to produce cancer vaccines that target cells within the tumor microenvironment. These vaccines aim to activate T cells—an important part of the immune system—to attack both tumor cells and suppressive immune cells that allow cancer to grow unchecked.
Source Fool.com
